| 產品名稱 |
HM2 |
| 商品貨號 |
B164620 |
| Organism |
human (T cell); human (T cell leukemia) |
| Cell Type |
hybridoma: helper T lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells Contain RETROVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
Leukemia,hepatitis |
| Applications |
The cells produce a SSF that specifically inhibits T cell dependent immune functions. NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS. Hepatitis B virus precautions are recommended by the depositor. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells. NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS. |
| Clinical Data |
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells. NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS. |
| Antigen Expression |
Leu 3a; CD4 |
| Genes Expressed |
soluble suppression factor (SSF),Leu 3a; CD4 |
| Cellular Products |
soluble suppression factor (SSF) |
| Comments |
T cells from a patient with acquired immunodeficiency syndrome (AIDS) were fused with K37.3.2 human T cell leukemia cells. The cells produce a SSF that specifically inhibits T cell dependent immune functions. NOTE: this line should be handled with care since one of the fusion partners was derived from a patient with AIDS. Hepatitis B virus precautions are recommended by the depositor. |
| Complete Growth Medium |
Culture medium: RPMI 1640, 90%; fetal bovine serum, 10%. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Name of Depositor |
Cornell Res. Fndn., Inc. |
| Deposited As |
human (T cell); human (T cell leukemia) |
| U.S. Patent Number |
|
| References |
Laurence JC. Human T cell hybridomas which produce immunosuppressive factors. US Patent 4,665,032 dated May 12 1987
|
